Hutch News

Hutch News

Stories tagged 'Marco Mielcarek'

Gentler treatment effective for many with graft-vs.-host disease

A new study finds halving standard steroid dose treats most acute GVHD just as well; could limit dangerous side effects

Feb. 19, 2015 | By Dr. Rachel Tompa / Fred Hutch News Service

Up to 70 percent of transplant patients develop acute graft-vs.-host disease. Standard treatment for GVHD, the steroid prednisone, carries its own host of side effects. Fred Hutch's Dr. Marco Mielcarek led a new study testing lower doses of prednisone in patients with acute GVHD -- with promising results.

View story >


Mielcarek lands $2.2 million GVHD grant

NHLBI grant will expand research into protective mechanisms of statins against severe acute graft-vs.-host disease in transplant patients

May 16, 2011 | By Dean Forbes

The Fred Hutchinson Cancer Research Center Clinical Research Division’s Dr. Marco Mielcarek has received $2.2 million from the National Institutes of Health’s National Heart, Lung and Blood Institute to continue research on whether statin treatment is effective at reducing the risk of graft-vs.-host disease in patients receiving an allogeneic stem cell transplant. While statins are a class of drugs for treating high cholesterol, they also have immune-modulating effects.

View story >


Post-transplant survival: A study of the gap between ethnic groups

Mielcarek, colleagues cite transplant-diagnosis delays among possible reasons for poor survival rates for African-American patients

July 21, 2005 | By COLLEEN STEELQUIST

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.